KARAKTERISTIK, MEKANISME AKSI, DAN EFIKASI VAKSIN DALAM VAKSINASI GLOBAL PANDEMI COVID-19
Sari
Abstract: Characteristics, Mechanism of Action, and Efficacy of Vaccine in The Global Vaccination of The Covid-19 Pandemic. This review considers vaccines developed against SARS-CoV-2 in the period of the Covid-19 pandemic. In this search, we will discuss the mechanism of action of each vaccine as well as its efficacy and safety. Four vaccines are currently in common use in various countries: Pfizer-BioNTech (USA), Moderna (USA), Astra-Zeneca (UK), and Janssen Johnson & Johnson (USA). In addition, there are two vaccines that are only used by a few countries: Novavax (USA) and SInovax (China) for which data are not widely studied. Pfizer and Moderna's efficacy for preventing disease or severe illness was 95–87.5% and 94.5–100%, respectively. The efficacy of Astra-Zeneca and Janssen Johnson & Johnson are around 70% and 57-72%, respectively. Meanwhile, Sinovax and Novavax vaccines have efficacy of about 65-90% and 60-89.7%, respectively, for prevention against Covid-19. The vaccination strategy is based on accelerating the administration of vaccines, so that as many subjects as possible can be vaccinated quickly to achieve herd immunity.
Keywords: COVID-19, effectiveness, efficacy, SARS-CoV-2, and vaccine
Teks Lengkap:
PDFReferensi
Barranco, R., Rocca, G., Molinelli, A., & Ventura, F. (2021). Controversies and Challenges of Mass Vaccination against SARS-CoV-2 in Italy: Medico-Legal Perspectives and Considerations. Healthcare (Basel, Switzerland), 9(9), 1163. https://doi.org/10.3390/healthcare9091163.
Chen, M., Yuan, Y., Zhou, Y., Deng, Z., Zhao, J., Feng, F., Zou, H., & Sun, C. (2021). Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infectious diseases of poverty, 10(1), 94. https://doi.org/10.1186/s40249-021-00878-5
CSSE JHU. (2021). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Diakses pada 14 Mei dari https://coronavirus.jhu.edu/map.html.
Cox, R. J., & Brokstad, K. A. (2020). Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nature reviews. Immunology, 20(10), 581–582. https://doi.org/10.1038/s41577-020-00436-4
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., dkk. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, N.Y.), 371(6529), eabf4063. https://doi.org/10.1126/science.abf4063
Emary, K., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., dkk. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England), 397(10282), 1351–1362. https://doi.org/10.1016/S0140-6736(21)00628-0
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, dkk. (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 181(7), 1489–1501.e15. https://doi.org/10.1016/j.cell.2020.05.015
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., dkk. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. The New England journal of medicine, 385(13), 1172–1183. https://doi.org/10.1056/NEJMoa2107659
Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., dkk. (2021). Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine, 385(10), 875–884. https://doi.org/10.1056/NEJMoa2107715
John, G. (King's College London) (2021). Vaccine Janssen data sheet). Diakses 6 April 2022 dari https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf.
Kumar, S., Nyodu, R., Maurya, V. K., & Saxena, S. K. (2020). Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics, 23–31. https://doi.org/10.1007/978-981-15-4814-7_3
Ling, Y., Zhong, J., & Luo, J. (2021). Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. Journal of medical virology, 93(12), 6486–6495. https://doi.org/10.1002/jmv.27203
Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021). Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and drug resistance, 14, 3459–3476. https://doi.org/10.2147/IDR.S315727
Novavax.com. (2021). Vaccine Novavax. Diakses 29 April 2022 dari https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines - a new era in vaccinology. Nature reviews. Drug discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
Sette, A., & Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 184(4), 861–880. https://doi.org/10.1016/j.cell.2021.01.007
Shimabukuro, T., & Nair, N. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA, 325(8), 780–781. https://doi.org/10.1001/jama.2021.0600
Suschak, J. J., Williams, J. A., & Schmaljohn, C. S. (2017). Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human vaccines & immunotherapeutics, 13(12), 2837–2848. https://doi.org/10.1080/21645515.2017.1330236
Vilches, T. N., Zhang, K., Van Exan, R., Langley, J. M., & Moghadas, S. M. (2021). Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine, 39(17), 2360–2365. https://doi.org/10.1016/j.vaccine.2021.03.058
Walsh, E. E., Frenck, R. W., Jr, Falsey, A. R., Kitchin, N., Absalon, J., dkk. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England journal of medicine, 383(25), 2439–2450. https://doi.org/10.1056/NEJMoa2027906
Zhou, X., Jiang, X., Qu, M., Aninwene, G. E., 2nd, Jucaud, V., Moon, J. J., Gu, Z., Sun, W., & Khademhosseini, A. (2020). Engineering Antiviral Vaccines. ACS nano, 14(10), 12370–12389. https://doi.org/10.1021/acsnano.0c06109
DOI: https://doi.org/10.33024/jikk.v9i2.6871
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc4.footer##
Pendidikan Dokter Universitas Malahayati Lampung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.